Eisai to Launch Pariet S, the First Proton Pump Inhibitor RX-to-OTC in Japan - Same Dosage of the Active Ingredient Rabeprazole Sodium as . Tuesday, 02 January 2024 12:17 GMT.

TOKYO, Jun 2, 2025--- Eisai Co., Ltd. announced today the launch of "Pariet S", which is highly effective in alleviating severe heartburn andstomach pain caused by gastric acid reflux, at ...

Proton pump inhibitors can induce the symptoms they are used to treat, which could spell trouble for people who take these drugs without a solid indication, researchers warn.

Prior epidemiologic results have suggested a possible association between chronic, long-term use of proton-pump inhibitors (PPIs) and excess risk for osteoporosis-related fractures (JW ...

A number of studies have evaluated the effect of proton-pump inhibitors on the risk of recurrent bleeding in patients with bleeding peptic ulcers. 7–13 Some of the studies did not use endoscopic ...

TOKYO, June 2, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today the launch of “Pariet®S” (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn ...

INTRODUCTION. Proton pump inhibitors (PPIs) are among the most prescribed drugs worldwide 1.Considered safe and efficient drugs, they have revolutionized the treatment of acid peptic disorders, in ...

Objective To determine whether proton pump inhibitors (PPIs) are associated with an increased risk of colorectal cancer, compared with histamine-2 receptor antagonists (H2RAs). Design The United ...

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). Design Using ...